Thomas A. Moulton
Columbia University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Thomas A. Moulton.
The Journal of Pediatrics | 1992
Joseph H. Graziano; Nancy J. Lolacono; Thomas A. Moulton; Mary Ellen Mitchell; Vesna Slavkovich; Concepcion Zarate
We examined the efficacy and safety of meso-2,3-dimercaptosuccinic acid (DMSA) in children with markedly elevated blood lead (BPb) concentrations. Among 19 children with BPb concentrations of 50 to 69 micrograms/dl (2.41 to 3.33 mumol/L) who received a 5-day inpatient oral course of DMSA (1050 mg/m2 per day), the mean BPb concentration decreased by 61%; in four who received calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA) (1000 mg/m2 per day intravenously), it decreased by 45% (p less than 0.0007). Urinary lead excretion was comparable in both groups. Treatment with DMSA was more effective than treatment with CaNa2EDTA in restoring metabolic activity to the heme pathway and was well tolerated even among nine patients who received concomitant iron supplementation and two who had homozygous deficiency of glucose-6-phosphate dehydrogenase. On discharge, these 19 children received either no chelation therapy or DMSA, 350 or 700 mg/m2 per day for 14 days on an outpatient basis. After 14 days the mean BPb values for the no-chelation, low-DMSA, and high-DMSA groups were 73%, 66%, and 50% of the pretreatment values, respectively. We conclude that a 5-day oral course of DMSA is effective in the treatment of children with severe lead poisoning. In addition, on an outpatient basis the administration of DMSA, 700 mg/m2 per day, is capable of delaying the typical rebound in BPb values and should ultimately reduce the need for repeated hospitalizations.
Cancer Immunology, Immunotherapy | 1991
Gary M. Graham; Ludovico Guarini; Thomas A. Moulton; Subashree Datta; Soldano Ferrone; Patrizio Giacomini; R. S. Kerbel; Paul B. Fisher
SummaryAdministration of interferon as a single therapeutic regimen in cancer patients with various neoplasias has had only limited efficacy in ameliorating the negative clinical course of their disease. In the present study, we have evaluated the effect of recombinant human fibroblast (IFNβ) and immune (IFNγ) interferon, alone and in combination, on growth, differentiation and the expression of class I and II histocompatibility locus antigens (HLA) and melanoma-associated antigens on the human melanoma cell line H0-1. The effect of combinations of interferons on the antigenic profile of human melanoma cells displaying different organ colonization and spontaneous metastatic potential in athymic nude mice was also determined. H0-1 cells were more sensitive to the antiproliferative activity of IFNβ than to IFNγ and the combination of interferons resulted in a potentiation of growth suppression. The antiproliferative effect of both interferons was greater in later-passage than in earlier-passage H0-1 cells, possibly reflecting alterations in the evolving tumor cell population as a result of long-term in vitro propagation and/or the selective outgrowth of cells with an increased growth rate. The enhanced growth suppression observed in H0-1 cells treated with the combination of IFNβ plus IFNγ was not associated with a significant increase in the level of melanin, a marker of melanoma differentiation, above that observed with either interferon used alone. IFNβ and IFNγ differentially modulated the expression of class I and II HLA and melanoma-associated antigens in H0-1 cells and a series of melanoma cells with different organ colonization and metastatic potential, including MeWo, MeM 50-10, MeM 50-17, 3S5 and 70W. No consistent potentiation or antagonism in the expression of any specific antigen was observed in any of the melanoma cell lines exposed to the combination of interferons. The present study demonstrates that the combination of IFNβ plus IFNγ can potentiate growth suppression in H0-1 human melanoma cells and that this effect is not associated with an increase in differentiation or a potentiation in antigenic modulation. In addition, no direct correlation between the expression of any specific antigen or its modulation by IFNβ or IFNγ, alone or in combination, and organ colonization and metastatic potential in nude mice was observed in the different melanoma cell lines.
Nature | 1993
Yue Hao; Taria Crenshaw; Thomas A. Moulton; Elizabeth W. Newcomb; Benjamin Tycko
Nature Genetics | 1994
Thomas A. Moulton; Taria Crenshaw; Yue Hao; Josh Moosikasuwan; Na Lin; Francine Dembitzer; Terrence Hensle; Lawrence M. Weiss; Lydia McMorrow; Thomas Loew; Wilma Kraus; William L. Gerald; Benjamin Tycko
American Journal of Pathology | 1995
Thomas A. Moulton; Ghassan J. Samara; Wai-Yee Chung; Luwa Yuan; Raj Desai; Michael B. Sisti; Jeffrey N. Bruce; Benjamin Tycko
Medical and Pediatric Oncology | 1996
Thomas A. Moulton; Wai-Yee Chung; Luwa Yuan; Terrence Hensle; Pamela G. Waber; Perry Nisen; Benjamin Tycko
International Journal of Cancer | 1990
Ludovico Guarini; Massimo Temponi; Jeffrey N. Bruce; Arthur P. Bollon; Gregory J. Duigou; Thomas A. Moulton; Soldano Ferrone; Paul B. Fisher
Environmental Health Perspectives | 1995
Patrick Asiedu; Thomas A. Moulton; Conrad B. Blum; Erlinda Roldan; Nancy J. Lolacono; Joseph H. Graziano
Journal of the National Cancer Institute | 1991
P. Gopal Reddy; Gary M. Graham; Subashree Datta; Ludovico Guarini; Thomas A. Moulton; Hongping Jiang; Michael M. Gottesman; Soldano Ferrone; Paul B. Fisher
Medical and Pediatric Oncology | 1994
Robert J. Wells; Lorrie F. Odom; Stuart Gold; James H. Feusner; Carl E. Krill; Peter Waldron; Thomas A. Moulton; Eva Knoppell; Michael White; Mitchell S. Cairo